Drospirenone

MECHANISM OF ACTION

Drospirenone is a synthetic progestin that primarily works by mimicking the effects of natural progesterone. It prevents ovulation by suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thickens cervical mucus to block sperm entry, and alters the endometrium to reduce the chance of implantation.

PHARMACOKINETICS

Absorption

The drug is highly protein-bound (~95%) and has a volume of distribution of 3–5 L/kg. Drospirenone is extensively metabolized in the liver via CYP3A4 and other pathways into inactive metabolites, which are primarily excreted in urine (≈50%) and feces (≈40%). Its elimination half-life is 24–30 hours, supporting once-daily dosing.

Distribution

Drospirenone has a volume of distribution of approximately 3–5 L/kg, indicating that the drug is well-distributed into body tissues beyond the bloodstream. Despite being highly protein-bound (~95%), this moderate volume of distribution allows effective tissue penetration, which contributes to its contraceptive and hormonal effects.

Metabolism

Drospirenone is extensively metabolized in the liver through both CYP3A4-mediated oxidation and non-CYP pathways, including lactone ring opening and conjugation. These processes produce mostly inactive metabolites, which are subsequently excreted in urine and feces.

Elimination

Drospirenone is primarily eliminated from the body as inactive metabolites, with only a small amount excreted unchanged. Approximately 50% of the metabolites are excreted in the urine and around 40% in the feces. Its elimination half-life of 24–30 hours allows for once-daily dosing and helps maintain stable plasma concentrations during continuous therapy.

PHARMACODYNAMICS

Drospirenone is a synthetic progestin that exerts its effects by mimicking natural progesterone. It prevents ovulation through suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thickens cervical mucus to block sperm entry, and alters the endometrial lining to reduce the chance of implantation. Additionally, Drospirenone has anti-mineralocorticoid activity, which helps reduce water retention and bloating, and anti-androgenic activity, improving acne and excess oil production.

ADMINISTRATION

Drospirenone is administered orally, usually in combination with ethinylestradiol, as a once-daily tablet at approximately the same time each day to maintain consistent hormone levels. It can be taken with or without food. Proper administration involves starting the first pill on the first day of the menstrual cycle or as directed by a healthcare provider, and following the prescribed sequence to ensure effective contraception.

DOSAGE AND STRENGTH

Drospirenone is commonly administered orally in combination with ethinylestradiol for contraceptive purposes. The typical tablet contains 3 mg of Drospirenone and 20–30 µg of ethinylestradiol, taken once daily at the same time each day for 21 consecutive days, followed by a 7-day pill-free interval or placebo tablets. This dosing regimen ensures consistent hormone levels for effective pregnancy prevention.

DRUG INTERACTIONS

Drospirenone can interact with several drugs that may affect its effectiveness or safety. CYP3A4 inducers, such as rifampin, carbamazepine, phenytoin, and St. John’s Wort, can increase Drospirenone metabolism, reducing contraceptive efficacy. CYP3A4 inhibitors like ketoconazole or erythromycin may slightly elevate Drospirenone levels, potentially increasing side effects. Concomitant use with potassium-sparing drugs, including ACE inhibitors, ARBs, or potassium supplements, can raise the risk of hyperkalemia due to its anti-mineralocorticoid activity.

FOOD INTERACTIONS

Drospirenone has no significant food interactions. It can be taken with or without meals without affecting absorption or effectiveness. Unlike some drugs that require food for better absorption or to reduce gastrointestinal side effects, Drospirenone maintains stable plasma levels regardless of food intake.

CONTRAINDICATIONS

Drospirenone is contraindicated in individuals with a history of venous thromboembolism, stroke, or myocardial infarction, as it may increase the risk of blood clots. It should not be used in patients with known hypersensitivity to Drospirenone or any component of the formulation, severe liver disease, orrenal impairment with elevated potassium levels, due to its anti-mineralocorticoid activity.

SIDE EFFECTS

• Nausea and vomiting 

• Breast tenderness 

• Headache or migraine 

• Irregular menstrual bleeding or spotting 

• Bloating or fluid retention

OVER DOSAGE

Drospirenone overdosage occurs when more than the recommended daily dose is taken, usually in combination with ethinylestradiol. Symptoms are generally mild and may include nausea, vomiting, breast tenderness, dizziness, fatigue, and abdominal discomfort. Serious complications are rare but could increase the risk of thromboembolic events in susceptible individuals.

TOXICITY

Drospirenone toxicity refers to harmful effects that may occur when the drug is taken in excessive amounts or in sensitive individuals. Toxicity can manifest as severe nausea, vomiting, dizziness, or electrolyte imbalances such as hyperkalemia due to its anti-mineralocorticoid activity. Overdose may also increase the risk of venous thromboembolism in predisposed patients.